Core Insights - Crescita Therapeutics reported its financial results for Q4 and fiscal year 2025, highlighting a decline in revenue for Q4 but an overall increase for the fiscal year, driven by successful asset integration and strategic acquisitions [1][4][5]. Financial Highlights Q4-2025 vs. Q4-2024 - Revenue decreased to $5,955 from $6,902, a decline of $947, primarily due to a reimbursement for unused inventory [5][17]. - Gross profit increased to $3,239 from $2,807, up $432, resulting in a gross margin of 54.4% compared to 40.7% [5][19]. - Operating expenses rose to $3,620 from $3,075, an increase of $545, mainly due to higher selling, general, and administrative expenses [5][22]. - Net loss widened to $(711) from $(162), an increase of $549 [5][14]. - Adjusted EBITDA decreased to $70 from $151, down $81 [5][14]. F2025 vs. F2024 - Total revenue for the fiscal year increased to $21,118 from $19,580, an increase of $1,538, attributed to higher skincare revenue and the impact of acquisitions [5][18]. - Gross profit rose to $11,109 from $8,990, up $2,119, with a gross margin of 52.6% compared to 45.9% [5][21]. - Operating expenses slightly decreased to $12,131 from $12,205, a reduction of $74 [5][23]. - Net loss improved to $(92) from $(2,750), a significant reduction of $2,658 [5][14]. - Adjusted EBITDA increased to $617 from $(1,541), an improvement of $2,158 [5][14]. Operational and Corporate Developments - Crescita announced a proposed acquisition by ClinActiv Holdings at a cash consideration of $0.80 per share, representing a 74% premium over the five-day volume weighted average price [6][7]. - The acquisition is expected to close in Q2 2026, subject to shareholder and court approvals [7][8]. - The company renewed its lease for its manufacturing and office facility for an additional five years [8]. - Crescita acquired assets from Laboratoire Provence-Canada Inc. for $775, enhancing its manufacturing capabilities [8]. - A mutual termination of the licensing agreement with Croma Pharma for Pliaglis® resulted in a termination payment of €575,000 (CA$902,000) [8].